|
1
|
Fitzmaurice C, Dicker D, Pain A, Hamavid
H, Moradi-Lakeh M, MacIntyre MF, Allen C, Hansen G, Woodbrook R,
Wolfe C, et al Global Burden of Disease Cancer Collaboration: The
global burden of cancer 2013. JAMA Oncol. 1:505–527. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pfister DG, Spencer S, Adelstein D, Adkins
D, Brizel DM, Burtness B, Busse PM, Caudell JJ, Cmelak AJ, Colevas
AD, et al: National Comprehensive Cancer Network: NCCN Clinical
Practice Guidelines in Oncology (NCCN Guidelines) Head and Neck
Cancers (Version 1). 2018, http://www.nccn.org. Accessed
February 15, 2018.
|
|
4
|
Amin MB, Greene FL, Edge SB, Compton CC,
Gershenwald JE, Brookland RK, Meyer L, Gress DM, Byrd DR and
Wincheser DP: American Joint Committee on Cancer-Cancer Staging
Manual. 8th edition. Springer; New York, NY: 2018
|
|
5
|
Pentenero M, Gandolfo S and Carrozzo M:
Importance of tumor thickness and depth of invasion in nodal
involvement and prognosis of oral squamous cell carcinoma: A review
of the literature. Head Neck. 27:1080–1091. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang MH, Wang D and Chen YQ: Oncogenic and
invasive potentials of human macrophage-stimulating protein
receptor, the RON receptor tyrosine kinase. Carcinogenesis.
24:1291–1300. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gaudino G, Follenzi A, Naldini L, Collesi
C, Santoro M, Gallo KA, Godowski PJ and Comoglio PM: RON is a
heterodimeric tyrosine kinase receptor activated by the HGF
homologue MSP. EMBO J. 13:3524–3532. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Muraoka RS, Sun WY, Colbert MC, Waltz SE,
Witte DP, Degen JL and Friezner Degen SJ: The Ron/STK receptor
tyrosine kinase is essential for peri-implantation development in
the mouse. J Clin Invest. 103:1277–1285. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Waltz SE, Eaton L, Toney-Earley K, Hess
KA, Peace BE, Ihlendorf JR, Wang MH, Kaestner KH and Degen SJ:
Ron-mediated cytoplasmic signaling is dispensable for viability but
is required to limit inflammatory responses. J Clin Invest.
108:567–576. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chen Q, Seol DW, Carr B and Zarnegar R:
Co-expression and regulation of Met and Ron proto-oncogenes in
human hepato-cellular carcinoma tissues and cell lines. Hepatology.
26:59–66. 1997.PubMed/NCBI
|
|
11
|
Maggiora P, Marchio S, Stella MC, Giai M,
Belfiore A, De Bortoli M, Di Renzo MF, Costantino A, Sismondi P and
Comoglio PM: Overexpression of the RON gene in human breast
carcinoma. Oncogene. 16:2927–2933. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lin HS, Berry GJ, Fee WE Jr, Terris DJ and
Sun Z: Identification of tyrosine kinases overexpressed in head and
neck cancer. Arch Otolaryngol Head Neck Surg. 130:311–316. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Camp ER, Liu W, Fan F, Yang A, Somcio R
and Ellis LM: RON, a tyrosine kinase receptor involved in tumor
progression and metastasis. Ann Surg Oncol. 12:273–281. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lee WY, Chen HH, Chow NH, Su WC, Lin PW
and Guo HR: Prognostic significance of co-expression of RON and MET
receptors in node-negative breast cancer patients. Clin Cancer Res.
11:2222–2228. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cheng HL, Liu HS, Lin YJ, Chen HH, Hsu PY,
Chang TY, Ho CL, Tzai TS and Chow NH: Co-expression of RON and MET
is a prognostic indicator for patients with transitional-cell
carcinoma of the bladder. Br J Cancer. 92:1906–1914. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Camp ER, Yang A, Gray MJ, Fan F, Hamilton
SR, Evans DB, Hooper AT, Pereira DS, Hicklin DJ and Ellis LM:
Tyrosine kinase receptor RON in human pancreatic cancer:
Expression, function, and validation as a target. Cancer.
109:1030–1039. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Welm AL, Sneddon JB, Taylor C, Nuyten DS,
van de Vijver MJ, Hasegawa BH and Bishop JM: The
macrophage-stimulating protein pathway promotes metastasis in a
mouse model for breast cancer and predicts poor prognosis in
humans. Proc Natl Acad Sci USA. 104:7570–7575. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Catenacci DV, Cervantes G, Yala S, Nelson
EA, El-Hashani E, Kanteti R, El Dinali M, Hasina R, Brägelmann J,
Seiwert T, et al: RON (MST1R) is a novel prognostic marker and
therapeut-ictarget for gastroesophageal adenocarcinoma. Cancer Biol
Ther. 12:9–46. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bieniasz M, Radhakrishnan P, Faham N, De
La OJP and Welm AL: Preclinical efficacy of Ron kinase inhibitors
alone and in combination with PI3K inhibitors for treatment of
sfRon-expressing breast cancer patient-derived xenografts. Clin
Cancer Res. 21:5588–5600. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yao HP, Zhou YQ, Ma Q, Guin S, Padhye SS,
Zhang RW and Wang MH: The monoclonal antibody Zt/f2 targeting RON
receptor tyrosine kinase as potential therapeutics against tumor
growth-mediated by colon cancer cells. Mol Cancer. 10:822011.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shah MA, Wainberg ZA, Catenacci DV,
Hochster HS, Ford J, Kunz P, Lee FC, Kallender H, Cecchi F, Rabe
DC, et al: Phase II study evaluating 2 dosing schedules of oral
foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with
metastatic gastric cancer. PLoS One. 8:e540142013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yoon TM, Kim SA, Park YL, Lee KH, Sung MW,
Lee JK, Lim SC, Chung IJ and Joo YE: Expression of the receptor
tyrosine kinase recepteur d'origine nantais and its association
with tumor progression in hypopharyngeal cancer. Head Neck.
35:1106–1113. 2013. View Article : Google Scholar
|
|
23
|
Edge SB, Byrd DR, Compton CC, Fritz AG,
Greene FL and Trotti A: American Joint Committee on Cancer-Cancer
Staging Manual. 7th edition. Springer; New York, NY: 2010
|
|
24
|
Xu XM, Wang D, Shen Q, Chen YQ and Wang
MH: RNA-mediated gene silencing of the RON receptor tyrosine kinase
alters oncogenic phenotypes of human colorectal carcinoma cells.
Oncogene. 23:8464–8474. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cho SB, Park YL, Song YA, Kim KY, Lee GH,
Cho DH, Myung DS, Park KJ, Lee WS, Chung IJ, et al: Small
interfering RNA-directed targeting of RON alters invasive and
oncogenic phenotypes of human hepatocellular carcinoma cells. Oncol
Rep. 26:1581–1586. 2011.PubMed/NCBI
|
|
26
|
Santamaria PG, Moreno-Bueno G, Portillo F
and Cano A: EMT: Present and future in clinical oncology. Mol
Oncol. 11:718–738. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wagner EF and Nebreda AR: Signal
integration by JNK and p38 MAPK pathways in cancer development. Nat
Rev Cancer. 9:537–549. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang D, Shen Q, Chen YQ and Wang MH:
Collaborative activities of macrophage-stimulating protein and
transforming growth factor-beta1 in induction of epithelial to
mesen-chymal transition: Roles of the RON receptor tyrosine kinase.
Oncogene. 23:1668–1680. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Xiangming X, Yun Q, Guoliang Z, Jianjiang
L and Lisong T: Mechanisms of RON-mediated epithelial-mesenchymal
transition in MDCK cells through the MAPK pathway. Braz J Med Biol
Res. 44:634–641. 2011.PubMed/NCBI
|
|
30
|
Wang D, Shen Q, Xu XM, Chen YQ and Wang
MH: Activation of the RON receptor tyrosine kinase attenuates
transforming growth factor-beta1-induced apoptotic death and
promotes phenotypic changes in mouse intestinal epithelial cells.
Carcinogenesis. 26:27–36. 2005. View Article : Google Scholar
|
|
31
|
Côté M, Miller AD and Liu SL: Human RON
receptor tyrosine kinase induces complete epithelial-to-mesenchymal
transition but causes cellular senescence. Biochem Biophys Res
Commun. 360:219–225. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lee CT, Chow NH, Su PF, Lin SC, Lin PC and
Lee JC: The prognostic significance of RON and MET receptor
coexpression in patients with colorectal cancer. Dis Colon Rectum.
51:1268–1274. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Song YA, Park YL, Kim KY, Myung E, Chung
CY, Cho SB, Lee WS, Jung YD, Kweon SS and Joo YE: RON is associated
with tumor progression via the inhibition of apoptosis and cell
cycle arrest in human gastric cancer. Pathol Int. 62:127–136. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Han WL, Li WD, Hu J, Rusidanmu A, Chen LF,
Shen L and Zheng SS: Expression of the recepteur d'originenantais
receptor tyrosine kinase in non-small cell lung cancer and its
clinical significance. Chin Med J (Engl). 125:1110–1114. 2012.
|
|
35
|
Ferrandina G, Martinelli E, Petrillo M,
Prisco MG, Zucconi A, Santaguida S, Zannoni G, Scambia G and
Ferlini C: Prognostic role of the recepteur d'origine nantais (RON)
expression in ovarian cancer patients. Gynecol Oncol. 111:237–243.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Cheng CT, Chen YY, Wu RC, Tsai CY, Chiang
KC, Yeh TS, Chen MH and Yeh CN: MET-RON dual inhibitor, BMS-777607,
suppresses cholangiocarcinoma cell growth, and MET-RON upregulation
indicates worse prognosis for intra-hepatic cholan-giocarcinoma
patients. Oncol Rep. 40:1411–1421. 2018.PubMed/NCBI
|
|
37
|
Ling Y, Kuang Y, Chen LL, Lao WF, Zhu YR,
Wang LQ and Wang D: A novel RON splice variant lacking exon 2
activates the PI3K/AKT pathway via PTEN phosphorylation in
colorectal carcinoma cells. Oncotarget. 8:39101–39116. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Krishnaswamy S, Mohammed AK, Tripathi G,
Alokail MS and Al-Daghri NM: Splice variants of the extracellular
region of RON receptor tyrosine kinase in lung cancer cell lines
identified by PCR and sequencing. BMC Cancer. 17:7382017.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Chakedis J, French R, Babicky M, Jaquish
D, Howard H, Mose E, Lam R, Holman P, Miyamoto J, Walterscheid Z,
et al: A novel protein isoform of the RON tyrosine kinase receptor
transforms human pancreatic duct epithelial cells. Oncogene.
35:3249–3259. 2016. View Article : Google Scholar :
|
|
40
|
Krishnaswamy S, Bukhari I, Mohammed AK,
Amer OE, Tripathi G, Alokail MS and Al-Daghri NM: Identification of
the splice variants of Recepteur d'Origine nantais (RON) in lung
cancer cell lines. Gene. 679:335–340. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Leighl NB, Tsao MS, Liu G, Tu D, Ho C,
Shepherd FA, Murray N, Goffin JR, Nicholas G, Sakashita S, et al: A
phase I study of foretinib plus erlotinib in patients with
previously treated advanced non-small cell lung cancer: Canadian
cancer trials group IND.196. Oncotarget. 8:69651–69662. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Yau TCC, Lencioni R, Sukeepaisarnjaroen W,
Chao Y, Yen CJ, Lausoontornsiri W, Chen PJ, Sanpajit T, Camp A, Cox
DS, et al: A phase I/II multicenter study of single-agent foretinib
as first-line therapy in patients with advanced hepatocellular
carcinoma. Clin Cancer Res. 23:2405–2413. 2017. View Article : Google Scholar :
|
|
43
|
LoRusso PM, Gounder M, Jalal SI, André V,
Kambhampati SRP, Loizos N, Hall J, Holzer TR, Nasir A, Cosaert J,
et al: Phase 1 study of narnatumab, an anti-RON receptor monoclonal
antibody, in patients with advanced solid tumors. Invest New Drugs.
35:442–450. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Feng L, Yao HP, Wang W, Zhou YQ, Zhou J,
Zhang R and Wang MH: Efficacy of anti-RON antibody Zt/g4-drug
maytan-sinoid conjugation (anti-RON ADC) as a novel therapeutics
for targeted colorectal cancer therapy. Clin Cancer Res.
20:6045–6058. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Chen JF, Yu BX, Yu R, Ma L, Lv XY, Cheng Y
and Ma Q: Monoclonal antibody Zt/g4 targeting RON receptor tyrosine
kinase enhances chemosensitivity of bladder cancer cells to
Epirubicin by promoting G1/S arrest and apoptosis. Oncol Rep.
37:721–728. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Suthe SR, Yao HP, Weng TH, Hu CY, Feng L,
Wu ZG and Wang MH: RON receptor tyrosine kinase as a therapeutic
target for eradication of triple-negative breast cancer: Efficacy
of anti-RON ADC Zt/g4-MMAE. Mol Cancer Ther. 17:2654–2664. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Yao HP, Feng L, Weng TH, Hu CY, Suthe SR,
Mostofa AGM, Chen LH, Wu ZG, Wang WL and Wang MH: Preclinical
efficacy of anti-RON antibody-drug conjugate Zt/g4-MMAE for
targeted therapy of pancreatic cancer overexpressing RON receptor
tyrosine kinase. Mol Pharm. 15:3260–3271. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Ruiz-Torres SJ, Benight NM, Karns RA,
Lower EE, Guan JL and Waltz SE: HGFL-mediated RON signaling
supports breast cancer stem cell phenotypes via activation of
non-canonical β-catenin signaling. Oncotarget. 8:58918–58933. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Ekiz HA, Lai SA, Gundlapalli H, Haroun F,
Williams MA and Welm AL: Inhibition of RON kinase potentiates
anti-CTLA-4 immunotherapy to shrink breast tumors and prevent
metastatic outgrowth. Oncoimmunology. 7:e14802862018. View Article : Google Scholar : PubMed/NCBI
|
